Literature DB >> 9385887

Prospective identification of myocardial stunning using technetium-99m sestamibi-based measurements of infarct size.

T F Christian1, M J Gitter, T D Miller, R J Gibbons.   

Abstract

OBJECTIVES: We sought to prospectively identify patients with stunning and hyperkinesia at hospital discharge on the basis of mismatches between left ventricular (LV) function and infarct size as assessed by technetium-99m (Tc-99m) sestamibi perfusion tomographic imaging.
BACKGROUND: Mechanical indexes of LV function may not accurately reflect myocardial damage after acute myocardial infarction (MI) because of myocardial stunning and compensatory hyperkinesia in noninfarct-related territories. Myocardial perfusion techniques are unaffected by these variables.
METHODS: Eighty-four patients with acute MI underwent hospital admission and discharge Tc-99m-sestamibi tomographic imaging. Global LV ejection fraction (LVEF) was measured at hospital discharge and 6 weeks later. The perfusion defect size was quantified and expressed as a percentage of the LV. The discharge perfusion defect, which is a measure of infarct size, was used to predict the 6-week LVEF for each patient based on a previously reported regression equation. Patients were classified into one of three groups depending on whether their LVEF at hospital discharge fell within, above or below one standard error (6.8 LVEF points) of the predicted 6-week LVEF.
RESULTS: There were 48 patients classified as having a "match" between function and infarct size; these patients demonstrated no significant change in LVEF at 6 weeks. There were 21 patients (25%) classified as "mismatch stunned" who had discharge LVEFs lower than those predicted by infarct size. These patients demonstrated a significant improvement in mean LVEF at 6 weeks (mean [+/-SD] discharge LVEF 0.41 +/- 0.08, 6-week LVEF 0.47 +/- 0.10; p = 0.003). Fifteen patients (18%) were classified as "mismatch-hyperkinetic." The mean LVEF for these patients significantly declined at 6 weeks (discharge LVEF 0.64 +/- 0.06, 6-week LVEF 0.58 +/- 0.09; p = 0.002). There was a marked increase in LVEF within the infarct zone (8 +/- 15 LVEF points; p = 0.03) for patients predicted to have stunning and a marked decline in LVEF outside the infarct zone (9 +/- 15 LVEF points; p = 0.06) in patients predicted to have hyperkinesia. Both discharge LVEF (p < 0.0001) and group classification (p = 0.005) were independent predictors of LVEF 6 weeks later.
CONCLUSIONS: Perfusion imaging with Tc-99m-sestamibi can identify post-MI patients at hospital discharge in whom LV function is discordant with the measured infarct size. Patients with stunning have late increases in LVEF; patients with hyperkinesia have late decreases. This methodology, performed at discharge, is predictive of late changes in LV function.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9385887     DOI: 10.1016/s0735-1097(97)00409-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  3 in total

Review 1.  Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction.

Authors:  J G F Cleland; A Torabi; N K Khan
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

2.  Nitrate-enhanced gated SPECT in patients with primary angioplasty for acute myocardial infarction: evidence of a reversible and nitrate-sensitive impairment of myocardial perfusion.

Authors:  Wassila Djaballah; Marc A Muller; Michael Angioï; Frédéric Moulin; Andrei Codreanu; Damien Mandry; Gérard Ethevenot; Gilles Karcher; Etienne Aliot; Pierre Y Marie
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-07-31       Impact factor: 9.236

3.  Early risk stratification using Rubidium-82 positron emission tomography in STEMI patients.

Authors:  Adam Ali Ghotbi; Philip Hasbak; Lars Nepper-Christensen; Jacob Lønborg; Kiril Atharovski; Thomas Christensen; Lene Holmvang; Thomas Engstrøm; Rasmus Sejersten Ripa; Andreas Kjær
Journal:  J Nucl Cardiol       Date:  2017-07-17       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.